Of all the research peptides discussed online, the CJC-1295 and Ipamorelin combination is probably the one whose published literature is most often misdescribed. Both molecules are real, both have been in formal clinical trials, and both have genuine pharmacological identities — which turn out to be more specific and more interesting than the internet usually conveys.
What: Two synthetic peptides that prompt the pituitary to release growth hormone through parallel pathways — CJC-1295 mimics GHRH, ipamorelin mimics ghrelin.
Research areas: Growth hormone and IGF-1 elevation · Post-operative ileus · GH deficiency · Visceral fat reduction · Combination pharmacology
Evidence: Both reached formal Phase 1/Phase 2 human trials with clear pharmacokinetic and endocrine effects; neither achieved regulatory approval. No peer-reviewed RCT of the combination as typically sold.
Status: Not approved anywhere. Both compounds are on the WADA Prohibited List (S2). Sold as research chemicals only.
What is CJC-1295?
CJC-1295 is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH), originally developed by the Canadian biopharmaceutical company ConjuChem in the mid-2000s. At the level of primary sequence, CJC-1295 is based on the first 29 amino acids of endogenous GHRH — the so-called GRF(1–29) or sermorelin fragment, which is the shortest sequence known to retain full GHRH receptor activity — modified at four residues to resist enzymatic degradation (Teichman et al., 2006).
There are, however, two distinct molecules commonly sold under the CJC-1295 name, and they are not interchangeable:
- CJC-1295 with DAC (Drug Affinity Complex). The molecule originally developed by ConjuChem. It carries a maleimidopropionic acid linker that covalently binds to serum albumin after injection, extending the circulating half-life from minutes to roughly a week. This was the version tested in the published Phase 1 and Phase 2 human trials.
- CJC-1295 without DAC, also known as modified GRF(1–29). This is the tetra-substituted GRF(1–29) sequence without the albumin-binding linker. It is a short-acting GHRH analog, with a half-life measured in minutes rather than days.
The distinction matters because these two molecules have fundamentally different pharmacokinetic (how long the drug stays in the body) profiles and would be expected to produce quite different growth hormone secretion patterns — one producing sustained elevation, the other producing a pulse and return to baseline.
What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide — five amino acids in total — belonging to the class of compounds known as Growth Hormone Secretagogues (GHS) or ghrelin receptor agonists. It was developed at Novo Nordisk in the mid-1990s and first described in detail by Raun and colleagues in a 1998 paper in the European Journal of Endocrinology (Raun et al., 1998).
The defining characteristic of ipamorelin in the published literature is its selectivity. Unlike earlier GHSs such as GHRP-6 and GHRP-2, ipamorelin was reported to stimulate growth hormone release in rats and pigs without meaningfully affecting cortisol, ACTH, or prolactin — a selectivity profile that was unusual for the GHS class at the time and which made ipamorelin of particular interest to Novo Nordisk as a potential therapeutic candidate (Raun et al., 1998).
Why they are studied together
The pairing of a GHRH analog with a ghrelin receptor agonist is not a casual combination — it reflects a well-characterized principle in neuroendocrinology that the two compound classes act on different receptors and through different intracellular pathways in the anterior pituitary somatotroph. GHRH activates its own G-protein-coupled receptor (GHRHR), driving cAMP-dependent GH synthesis and release. Ghrelin receptor agonists activate the GHS-R1a receptor, signaling through a largely independent phospholipase C / IP3 / calcium pathway (Kojima & Kangawa, 2005).
Published studies have repeatedly reported that combining a GHRH with a ghrelin receptor agonist produces synergistic (greater-than-additive) growth hormone release, rather than simple additive effects. This synergy was first characterized in detail for the combinations of GHRH with GHRP-6 and related peptides in human volunteers (Bowers et al., 1990), and the principle generalizes across the class.
The CJC-1295 + ipamorelin pairing is therefore a pharmacological archetype: a long- or short-acting GHRH analog combined with a selective ghrelin receptor agonist, exploiting two parallel signaling pathways to produce a GH pulse larger than either agent alone.
Proposed mechanisms
CJC-1295 (and the GHRH pathway)
GHRH binds to the GHRH receptor on pituitary somatotrophs (the GH-producing cells of the anterior pituitary), activating adenylyl cyclase and raising intracellular cAMP. This in turn activates protein kinase A, drives calcium influx through voltage-gated channels, and triggers exocytosis of pre-formed GH granules. Over a longer timescale, GHRH also stimulates GH gene transcription via CREB (Frohman & Kineman, 2002). CJC-1295's modifications are designed to preserve this activity while resisting cleavage by dipeptidyl peptidase IV (DPP-IV), the principal degrading enzyme that limits the half-life of native GHRH to just a few minutes in circulation (Jetté et al., 2005).
Ipamorelin (and the GHS-R1a pathway)
The GHS-R1a receptor is the endogenous receptor for ghrelin, a 28-amino-acid peptide produced primarily in the stomach that acts as a powerful GH secretagogue and appetite stimulant. Ipamorelin and its congeners mimic ghrelin's action at GHS-R1a without the full spectrum of ghrelin's metabolic effects. Activation of GHS-R1a drives GH release via a calcium-dependent mechanism and, in the presence of GHRH signaling, amplifies the resulting GH pulse considerably (Smith et al., 1997).
Published studies report that ipamorelin's selectivity — releasing GH without stimulating ACTH, cortisol, or prolactin — distinguishes it from earlier GHSs such as hexarelin and GHRP-2, which produce measurable cortisol and prolactin elevations (Raun et al., 1998).
The literature uses overlapping terms. "GHRP" (Growth Hormone Releasing Peptide) historically refers to a family including GHRP-2, GHRP-6, hexarelin, and ipamorelin. The modern term "ghrelin receptor agonist" or "GHS-R1a agonist" is more mechanistically accurate. Older papers may use GHRP terminology even when discussing ipamorelin.
Key research
CJC-1295 Phase 1 trial
The landmark published human trial of CJC-1295 with DAC was a Phase 1 study reported by Teichman and colleagues in The Journal of Clinical Endocrinology & Metabolism in 2006. The study was a randomized, placebo-controlled single ascending dose trial in healthy adult volunteers. The authors reported that single subcutaneous doses of CJC-1295 produced dose-dependent increases in circulating GH and, consequently, sustained elevations in insulin-like growth factor 1 (IGF-1). Effects on IGF-1 persisted for more than a week following a single administration, consistent with the extended half-life conferred by albumin binding (Teichman et al., 2006).
CJC-1295 pharmacodynamics
A companion paper from the same research group characterized the pharmacokinetic and pharmacodynamic profile in more detail, reporting a terminal half-life of approximately 5.8 to 8.1 days and a prolonged effect on GH pulsatility (Ionescu & Frohman, 2006). Of note, the published analysis reported that CJC-1295 did not obliterate normal GH pulsatility — rather, it amplified the baseline and the pulses around it, maintaining the episodic release pattern that appears to be important for preserving downstream GH signaling.
Ipamorelin preclinical characterization
The Raun et al. 1998 paper is the canonical pharmacological description of ipamorelin. Working in rat and pig models, the Novo Nordisk team reported that ipamorelin was at least as potent as GHRP-6 in stimulating GH release, but distinguished by its failure to elevate cortisol, ACTH, or prolactin at GH-releasing doses. The authors characterized receptor-binding affinity, selectivity against related receptors, and dose-response curves in detail (Raun et al., 1998).
Ipamorelin pharmacokinetics in humans
Published human pharmacokinetic data for ipamorelin reported a terminal half-life of approximately two hours after intravenous administration, with GH release occurring in a pulsatile pattern closely mirroring dose administration (Gobburu et al., 1999).
Comparison with older GHRPs
A body of work from the 1990s and early 2000s compared the various GHSs head-to-head. GHRP-2 remains the most potent GH releaser in the class but produces measurable increases in cortisol and prolactin. Hexarelin is potent but shows tachyphylaxis (diminishing response with repeated administration) and also elevates cortisol. Ipamorelin, according to the published comparative literature, has lower peak GH-releasing potency than GHRP-2 but offers a cleaner endocrine profile — the trade-off that originally motivated its development at Novo Nordisk (Pihoker et al., 1997).
GH pulsatility and combination studies
A substantial literature exists on the combination of GHRH with ghrelin receptor agonists. Bowers and colleagues first characterized the synergy in human volunteers using GHRH + GHRP-6, reporting that the combination produced GH peaks substantially higher than either agent alone (Bowers et al., 1990). Subsequent work extended these findings to GHRP-2 and, in later studies, to combinations involving CJC-1295 and ipamorelin in preclinical and veterinary contexts (Alba et al., 2006).
Post-operative ileus trial
Ipamorelin was taken into Phase 2 clinical development by Helsinn Therapeutics for the treatment of post-operative ileus — the temporary paralysis of gut motility following abdominal surgery. Published results from a Phase 2b trial reported that ipamorelin was well-tolerated but did not meet its primary efficacy endpoint in that indication, and the program was subsequently discontinued (Beck et al., 2014).
Clinical development history
Both compounds have genuinely been in human clinical trials — a fact that distinguishes them from many of their research-peptide contemporaries. CJC-1295 was tested by ConjuChem in Phase 1 and early Phase 2 studies for indications including visceral fat reduction and growth hormone deficiency. Publicly disclosed information indicates that development was ultimately paused, with the program never reaching pivotal Phase 3 trials (ConjuChem, 2007).
Ipamorelin, as noted, was developed through Phase 2 for post-operative ileus and also examined in investigator-led research for other indications. Neither compound holds market authorization from the EMA, MHRA, FDA, or any comparable regulator.
Current state of evidence
As always, a careful reading distinguishes categories of evidence:
- Strong evidence for acute GH/IGF-1 elevation. Both compounds, individually and in combination, have been reliably reported in published human and animal studies to elevate growth hormone secretion in the short term. This pharmacological effect is well-characterized.
- Strong pharmacokinetic characterization. The half-lives, distribution, and dose-response relationships of both molecules have been described in published studies.
- Limited long-term efficacy data in any specific clinical indication. Neither compound achieved approval for any use. Published trials are short-duration and focus on endocrine parameters rather than long-term clinical outcomes.
- No published human RCT data on "CJC-1295 + ipamorelin" as a named combination therapy in the form it is typically marketed as a research chemical stack.
Safety findings from trials
In the published Phase 1 trial of CJC-1295, reported adverse events were generally mild and transient, most commonly involving injection site reactions and occasional flushing or headache (Teichman et al., 2006). One note of caution: later safety reports connected to the ConjuChem program raised concerns about an unexpected serious adverse event during a distinct clinical study, which contributed to the pause in development. This history is documented in regulatory and company communications rather than in the primary peer-reviewed literature.
For ipamorelin, published trial data describe a generally favorable tolerability profile at the doses tested, consistent with the compound's endocrine selectivity (Beck et al., 2014).
What the research does not show
- No demonstrated long-term clinical benefit in any approved indication for either compound.
- No head-to-head Phase 3 trial data comparing the CJC-1295 + ipamorelin combination with established GH therapies.
- Efficacy for body composition, sleep quality, or recovery claims frequently discussed online is not supported by randomized controlled evidence at the level typically required for therapeutic claims.
- Long-term safety profile beyond the trial durations is uncharacterized, including effects on insulin sensitivity, glucose tolerance, and cancer risk that have been concerns for GH therapy more broadly.
Published dosing ranges
In the peer-reviewed Phase 1 trial, single doses of CJC-1295 with DAC tested in the dose-escalation cohort ranged from approximately 30 μg/kg to 250 μg/kg, with dose-dependent effects on circulating IGF-1 reported across the range (Teichman et al., 2006). For ipamorelin, Novo Nordisk's Phase 1 and Phase 2 published data examined doses in the range of approximately 0.01 to 1 mg intravenous bolus in humans (Gobburu et al., 1999).
These figures are reported here as literature values — not instructions. No established research-chemical-market protocol exists in the peer-reviewed literature.
WADA status
Both CJC-1295 and ipamorelin, along with other growth hormone-releasing peptides and ghrelin receptor agonists, are listed on the World Anti-Doping Agency Prohibited List under S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. The prohibition applies at all times in and out of competition (WADA, 2024).
This article is a summary of published research. Where dosing is discussed, the context is always "in published clinical trials, doses ranged from X to Y." At no point should this be read as instruction for human use. Neither compound is approved as a medicine in any major jurisdiction. There is no established research-chemical-market protocol in the peer-reviewed literature.